Published in Clin Oncol (R Coll Radiol) on January 01, 1997
Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer (2006) 3.26
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ (2000) 3.09
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer (2006) 1.56
Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol (2011) 1.01
Chemoradiotherapy for colorectal cancer. Gut (2005) 0.93
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer (2002) 0.91
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. Br J Cancer (2010) 0.84
Prognostic factors of pulmonary metastasectomy for colorectal carcinomas. World J Surg (2009) 0.81
Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome. Gastroenterol Res Pract (2012) 0.79
A single centre experience of first "one hundred laparoscopic liver resections". HPB Surg (2014) 0.78
Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors. Cancer Res Treat (2016) 0.75
Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. Radiat Oncol (2015) 0.75
Size of metastatic deposits affects prognosis in patients undergoing pulmonary metastectomy for colorectal cancer. Ann R Coll Surg Engl (2014) 0.75
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (2005) 3.75
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol (1999) 2.25
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Rural and urban differences in stage at diagnosis of colorectal and lung cancers. Br J Cancer (2001) 2.12
Randomised consent designs in cancer clinical trials. Eur J Cancer (1995) 2.07
Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer (2000) 1.97
A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer (1991) 1.93
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol (2002) 1.87
Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer (2004) 1.80
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. Clin Oncol (R Coll Radiol) (2006) 1.74
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet (2002) 1.68
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res (1999) 1.57
Impact of deprivation and rural residence on treatment of colorectal and lung cancer. Br J Cancer (2002) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer (2011) 1.53
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer (2001) 1.52
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer (2002) 1.49
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
New transtracheal bronchoalveolar lavage technique for the diagnosis of respiratory disease in sheep. Vet Rec (2005) 1.41
Systematic review of cancer treatment programmes in remote and rural areas. Br J Cancer (1999) 1.39
Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol (R Coll Radiol) (1997) 1.38
Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med (1974) 1.34
Phase I and pharmacokinetic study of rhizoxin. Cancer Res (1992) 1.26
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer (2009) 1.25
Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res (1987) 1.24
Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer (1999) 1.24
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res (1998) 1.21
Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene (2006) 1.20
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res (1986) 1.19
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol (1996) 1.18
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res (1993) 1.18
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol (2002) 1.16
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep (1980) 1.15
Effect of cigarette smoking and breathing carbon monoxide on cardiovascular hemodynamics in anginal patients. Circulation (1974) 1.14
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol (1996) 1.14
Family members as third parties in dyadic family conflict: strategies, alliances, and outcomes. Child Dev (1988) 1.13
Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer (2004) 1.12
An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer (1987) 1.10
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer (1997) 1.09
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol (2001) 1.09
A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer (2000) 1.08
Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer (2000) 1.08
Detection of Mycobacterium bovis infection in skin test-negative cattle with an assay for bovine interferon-gamma. Vet Rec (1994) 1.07
Neonatal extracorporeal membrane oxygenation: practice patterns and predictors of outcome in the UK. Arch Dis Child Fetal Neonatal Ed (2008) 1.07
Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res (1998) 1.06
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer (2005) 1.06
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer (1999) 1.06
Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer (2001) 1.04
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res (2001) 1.04
Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol (1998) 1.04
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer (1998) 1.02
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol (2012) 1.01
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? Br J Cancer (1994) 1.00
The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol) (1997) 0.99
Use of capecitabine in management of early colon cancer. Cancer Manag Res (2011) 0.99
c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer (2002) 0.99
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res (2000) 0.98
Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer (2009) 0.97
Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol (1996) 0.96
Utilising handheld computers to monitor and support patients receiving chemotherapy: results of a UK-based feasibility study. Support Care Cancer (2006) 0.96
Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer (1998) 0.95
Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin Pharmacol Ther (2010) 0.95
A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol (1995) 0.95
Therapeutic opportunities from tumour biology in metastatic colon cancer. Eur J Cancer (2000) 0.93
Preschoolers' attention to and memory for attachment-relevant information. Child Dev (1997) 0.93
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res (1998) 0.93
Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer (1991) 0.93
More money is needed to care for patients with cancer. BMJ (1997) 0.93
Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet (2000) 0.92
Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology (1992) 0.91
Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res (1999) 0.90
Effect of ethanol on angina pectoris. Ann Intern Med (1976) 0.89
External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer (2003) 0.89
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol (2008) 0.88
Effect of smoking marihuana and of a high-nicotine cigarette on angina pectoris. Clin Pharmacol Ther (1975) 0.88
The evolution of fluoropyrimidine therapy: from intravenous to oral. Oncologist (2001) 0.87
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol (1999) 0.87
Effect of carbon monoxide on maximal treadmill exercise. A study in normal persons. Ann Intern Med (1975) 0.87
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther (2008) 0.87
Patient-focused delivery promises to reshape hospitals. Health Prog (1992) 0.86
Potentiation of arginine-induced glucagon secretion by adenosine. Life Sci (1981) 0.86
Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer (2003) 0.86